Biotechnology

Ona Therapeutics to develop ADC with WuXi’s payload-linker platform

WuXi XDC Cayman has signed an agreement to provide Ona Therapeutics with an exclusive global licence to its WuXiTecan-2 payload-linker technology platform for the development of an antibody-drug conjugate (ADC) candidate.

Cellares and GenomeFrontier to assess automated GF-CART01 production

Cellares and GenomeFrontier Therapeutics have announced a collaboration to assess automated manufacturing for the latter’s investigational CAR-T cell therapy, GF-CART01, on the Cell Shuttle platform.

Exegenesis Bio and Modalis sign research deal for Duchenne therapy

Exegenesis Bio and Modalis Therapeutics have entered a research partnership and licence agreement to progress MDL-201, a therapeutic candidate for Duchenne muscular dystrophy (DMD).

ABEC to expand global manufacturing network with new Wilson facility

ABEC is set to open a new manufacturing facility in Wilson, North Carolina, US, expanding its network for biopharmaceutical process equipment and consumables.

Solstice Oncology secures $225m to drive porustobart’s development for cancer

Harbour BioMed’s partner Solstice Oncology has raised $225m in funding to advance its lead candidate, porustobart, a neoadjuvant immuno-oncology therapy.

LSTM opens $23m robotic AI lab for infection research

The Liverpool School of Tropical Medicine (LSTM) in the UK has opened a £20m ($23.2m) robotic AI laboratory to test drugs and vaccines against infections and diseases.

Biocytogen and Qilu Pharmaceutical sign agreement for VHH antibody molecule

China-based Biocytogen Pharmaceuticals has entered a non-exclusive licensing agreement with Qilu Pharmaceutical for a fully human VHH antibody molecule.

Novartis signs deal with Alteogen for drug delivery

Novartis has signed an agreement with Alteogen that could be worth up to $3.22bn for the development and commercialisation of subcutaneous drug formulations using Alteogen’s ALT-B4 technology.

AusperBio raises $120m to progress hepatitis B therapies

AusperBio Therapeutics and Ausper Biopharma have closed a Series C funding round worth $120m to support the development of new therapies for chronic hepatitis B (CHB).